Needham Maintains Buy on ShockWave Medical, Lowers Price Target to $260
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a 'Buy' rating on ShockWave Medical (NASDAQ:SWAV) but lowers the price target from $265 to $260.

November 07, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a 'Buy' rating on ShockWave Medical but lowers the price target from $265 to $260.
The news is directly related to ShockWave Medical. While the 'Buy' rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact on the stock price is uncertain as the rating is still 'Buy'.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100